scholarly journals Real-World Data Explores New Gene Expression Profiles in Breast Cancer

2021 ◽  
Vol 43 (3) ◽  
pp. 33-33
Author(s):  
Sarah LaCorte
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Real World ◽  
Expression Profiles ◽  
Gene Expression Profiles ◽  
Real World Data ◽  
World Data ◽  
New Gene

Abstract OT3-17-02: The FLEX real world data platform explores new gene expression profiles and investigator-initiated protocols in early stage breast cancer

2020 ◽  
Author(s):  
Jennifer A Crozier ◽  
Gordan Srkalovic ◽  
Adam Brufsky ◽  
Mehran Habibi ◽  
Pat Whitworth ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Real World ◽  
Early Stage ◽  
Expression Profiles ◽  
Gene Expression Profiles ◽  
Early Stage Breast Cancer ◽  
Real World Data ◽  
Data Platform ◽  
New Gene

scholarly journals MammaPrint, BluePrint, and full-genome data linked with clinical data to evaluate new gene EXpression profiles (FLEX): a real-world dataset and investigator-initiated protocols in ESBC

The Breast ◽  
2021 ◽  
Vol 56 ◽  
pp. S62
Author(s):  
J.A. Crozier ◽  
L. Blumencranz ◽  
M. Kleijn ◽  
H. Kling ◽  
A. Truitt ◽  
...  
Keyword(s):  
Gene Expression ◽  
Clinical Data ◽  
Real World ◽  
Expression Profiles ◽  
Gene Expression Profiles ◽  
Full Genome ◽  
Genome Data ◽  
New Gene

scholarly journals Cost of breast cancer based on real-world data: a cancer registry study in Italy

2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Stefano Capri ◽  
Antonio Russo
Keyword(s):  
Breast Cancer ◽  
Cancer Registry ◽  
Real World ◽  
Registry Study ◽  
Real World Data ◽  
World Data

Abstract PS9-63: Real world data on the adoption of trastuzumab biosimilars in the treatment of HER2-positive breast cancer

2021 ◽  
Author(s):  
William A Flood ◽  
Tiffany Avery ◽  
Vlad Kozlovsky ◽  
Neil Margolis ◽  
Sandeep Reddy
Keyword(s):  
Breast Cancer ◽  
Real World ◽  
Her2 Positive ◽  
Real World Data ◽  
World Data ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

Real-world cost-effectiveness of pertuzumab (P) with trastuzumab + chemo (T+Chemo) in patients (pts) with metastatic breast cancer (MBC): A population-based retrospective cohort study by the Canadian Real-world Evidence for Value in Cancer Drugs (CanREValue) collaboration.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 1048-1048
Author(s):  
Wei Fang Dai ◽  
Jaclyn Marie Beca ◽  
Chenthila Nagamuthu ◽  
Ning Liu ◽  
Maureen E. Trudeau ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cost Effectiveness ◽  
Incremental Cost ◽  
Real World ◽  
Retrospective Cohort ◽  
Health Technology ◽  
Population Based ◽  
Net Benefit ◽  
Real World Data ◽  
World Data

1048 Background: Addition of P to T+chemo for MBC pts has been shown to improve overall survival (OS) in a pivotal randomized trial (hazard ratio [HR] = 0.66, 95% CI: 0.52, 0.84) (Baselga et al., NEJM 2012). In Canada, the manufacturer submission to the health technology assessment agency estimated that P produced 0.64 life years gained (LYG) with an incremental cost-effectiveness ratio (ICER) of $187,376/LYG over 10 years (CADTH-pCODR, 2013). This retrospective cohort analysis aims to determine the comparative real-world population-based effectiveness and cost-effectiveness of P among MBC pts in Ontario, Canada. Methods: MBC pts were identified from the Ontario Cancer Registry and linked to the New Drug Funding Program database to identify receipt of treatment between 1/1/2008 and 3/31/2018. Cases received P-T-chemo after universal public funding of P (Nov 2013) and controls received T-chemo before. Demographic (age, socioeconomic, rurality) and clinical (comorbidities, prior adjuvant treatments, prior breast cancer surgery, prior radiation, stage at diagnosis, ER/PR status) characteristics were identified from linked admin databases balanced between cases and controls using propensity score matching. Kaplan-Meier methods and Cox regressions accounting for matched pairs were used to estimate median OS and HR. 5-year mean total costs from the public health system perspective were estimated from admin claims databases using established direct statistical methods and adjusted for censoring of both cost and effectiveness using inverse probability weighting. ICERs and 95% bootstrapped CIs were calculated, along with incremental net benefit (INB) at various willingness-to-pay values using net benefit regression. Results: We identified 1,823 MBC pts with 912 cases and 911 controls (mean age = 55 years), of which 579 pairs were matched. Cases had improved OS (HR = 0.66; 95% CI: 0.57, 0.78), with median 3.4 years, compared to controls median OS of 2.1. P provided an additional 0.63 (95% CI: 0.48 – 0.84) LYG at an incremental cost of $196,622 (95% CI: $180,774, $219,172), with a mean ICER = $312,147/LYG (95% CI: $260,752, $375,492). At threshold of $100,000/LYG, the INB was -$133,632 (95% CI: -$151,525, -$115,739) with < 1% probability of being cost-effective. Key drivers of incremental cost increase between groups included drug and cancer clinic costs. Conclusions: The addition of P to T-chemo for MBC increased survival but at significant costs. The ICER based on direct real-world data was higher than the initial economic model due to higher total costs for pts receiving P. This study demonstrated feasibility to derive ICER from person-level real-world data to inform cancer drug life-cycle health technology reassessment.

Identify Breast Cancer Subtypes by Gene Expression Profiles

2021 ◽  
Vol 2 (2) ◽  
pp. 165-175
Author(s):  
Grace S. Shieh ◽  
Chy-Huei Bai ◽  
Chih Lee
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Expression Profiles ◽  
Gene Expression Profiles ◽  
Breast Cancer Subtypes ◽  
Cancer Subtypes
Sign in / Sign up

Export Citation Format

Share Document